A study of the link between bone turnover markers and bone mineral density with inflammation and body mass in postmenopausal women with active rheumatoid arthritis

2012 ◽  
Vol 31 (2) ◽  
pp. 169-176 ◽  
Author(s):  
Anna Straburzyńska-Lupa ◽  
Alicja Nowak ◽  
Wojciech Romanowski ◽  
Paweł Korman ◽  
Łucja Pilaczyńska-Szcześniak
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Mineral Density ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Body Mass ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Active Rheumatoid Arthritis ◽  
Mineral Density ◽  
Turnover Markers

The study of bone mineral density and bone turnover markers in postmenopausal women with active rheumatoid arthritis

2005 ◽  
Vol 15 (6) ◽  
pp. 410-414 ◽  
Author(s):  
Shigeki Momohara ◽  
Hiroshi Okamoto ◽  
Toru Yago ◽  
Takefumi Furuya ◽  
Yuki Nanke ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Mineral Density ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Active Rheumatoid Arthritis ◽  
Mineral Density ◽  
Turnover Markers

scholarly journals Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
A. Sánchez ◽  
L. R. Brun ◽  
H. Salerni ◽  
P. R. Costanzo ◽  
D. González ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Control Group ◽  
Bone Resorption Marker ◽  
Similar Response ◽  
Mineral Density ◽  
Turnover Markers

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab.Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.

Three-month changes in bone turnover markers and bone mineral density response to raloxifene in Japanese postmenopausal women with osteoporosis

2008 ◽  
Vol 26 (2) ◽  
pp. 178-184 ◽  
Author(s):  
Takafumi Majima ◽  
Akira Shimatsu ◽  
Noriko Satoh ◽  
Yasato Komatsu ◽  
Atsushi Fukao ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Mineral Density ◽  
Density Response ◽  
Turnover Markers

Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis

2016 ◽  
Vol 98 (6) ◽  
pp. 580-585 ◽  
Author(s):  
Giovanni Orsolini ◽  
Giovanni Adami ◽  
Silvano Adami ◽  
Ombretta Viapiana ◽  
Luca Idolazzi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Mineral Density ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Tnf Inhibitors ◽  
Mineral Density ◽  
Short Term ◽  
Turnover Markers ◽  
Short Term Effects
Sign in / Sign up

Export Citation Format

Share Document